News Search Results
Oct 22, 2025, 02:00 ET ACM Biolabs Reports Favorable Safety Signals and Early Pharmacodynamics from Intramuscular Administration of ACM-CpG in Patients with Advanced Solid Tumors
SINGAPORE, Oct. 22, 2025 /PRNewswire/ -- ACM Biolabs, a clinical-stage biotechnology company developing next-generation nanoparticle-based immunotherapies, today announced encouraging early clinical findings from its ongoing Phase
More news about: ACM Biolabs
Oct 22, 2025, 02:00 ET ACM Biolabs Reports Favorable Safety Signals and Early Pharmacodynamics from Intramuscular Administration of ACM-CpG in Patients with Advanced Solid Tumors
SINGAPORE, Oct. 22, 2025 /PRNewswire/ -- ACM Biolabs, a clinical-stage biotechnology company developing next-generation nanoparticle-based immunotherapies, today announced encouraging early clinical findings from its ongoing Phase
More news about: ACM Biolabs
Oct 21, 2025, 10:00 ET Exosome Technology Licensed to PranaX Published in Nature Communications
HOUSTON, Oct. 21, 2025 /PRNewswire/ -- PranaX Corporation, a leading biotechnology company specializing in regenerative biologics, has announced that a study concerning the exosome manufacturing technology exclusively licensed
More news about: PranaX
Oct 21, 2025, 09:20 ET Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
identifying genetically modified cell lines to address hard to treat diseases while developing targeted cell-based treatments through innovative biotechnology partnerships. Back in June 2025, Avant announced plans to create a new company to house a joint venture, partnership,
More news about: Equity Insider
Oct 21, 2025, 09:00 ET The Galien Foundation Hosts 2025 Galien Week of Innovation to Showcase Advancements in Research, Diagnosis, and Treatment
This virtual webinar will bring together the nominees for the Best Biotechnology Product category, allowing participants to explore and examine the latest innovations in the biotechnology space.
More news about: The Galien Foundation
Oct 21, 2025, 09:00 ET HighVista Strategies Raises $270 Million for Oversubscribed Venture Capital Fund
strategies span private markets, including private credit, lower middle market private equity and early-stage venture capital; public markets, including biotechnology equities and hedged public markets strategies; as well as multi-strategy alternatives. Important Disclosure
More news about: HighVista Strategies LLC
Oct 21, 2025, 08:30 ET Halozyme to Report Third Quarter 2025 Financial and Operating Results
at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and
More news about: Halozyme Therapeutics, Inc.
Oct 21, 2025, 08:30 ET Improving Translational Research and Clinical Trials with Digital Pathology, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 21, 2025, 08:30 ET Beyond the bench: The advantages of GMP over USP compounding in early phase development, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 21, 2025, 08:30 ET CMC Development Strategies to Prevent Rework and Delays, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 21, 2025, 08:30 ET Immusoft Receives FDA Fast Track Designation for ISP-001, a First-in-Class Engineered B Cell Therapy for MPS I
SAN FRANCISCO, Oct. 21, 2025 /PRNewswire/ -- Immusoft of CA, a clinical-stage biotechnology company pioneering engineered B cell therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation
More news about: Roberts Communications
Oct 21, 2025, 08:30 ET Recent RWE Data Show Cell-Based Influenza Vaccines Offer 20% Greater Protection in the Prevention of Test-Confirmed Influenza in Pediatric and Adult Populations Relative to Standard Egg-Based Influenza Vaccines
CSL (ASX: CSL; USOTC: CSLLY) is a global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza,
More news about: CSL Seqirus
Oct 21, 2025, 08:17 ET MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman
The litigation is focused on the propriety of MoonLake's statements about the trial design and data for SLK. The clinical stage biotechnology company is focused on skin inflammatory diseases driven by a cytokines known as IL-17A and IL-17F. Central to SLK's commercial
More news about: Hagens Berman Sobol Shapiro LLP
Oct 21, 2025, 08:05 ET Clinical Proof-of-Concept Data for DNA-Encoded Monoclonal Antibodies (DMAbs) Published in Nature Medicine
PLYMOUTH MEETING, Pa., Oct. 21, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious
More news about: INOVIO Pharmaceuticals, Inc.
Oct 21, 2025, 08:00 ET Avant Technologies and Austrianova Launch Klothonova, Begin Developing Age Related Cellular Therapies Using 'Longevity Protein' Klotho
Oct. 21, 2025 /PRNewswire/ -- Avant Technologies Inc. (OTCQB: AVAI) ("Avant" or the "Company") and global biotechnology firm, Austrianova, today announced the official launch of their joint venture, Klothonova LLC, and its groundbreaking Klotho development program.
More news about: Avant Technologies Inc.
Oct 21, 2025, 08:00 ET Antheia Appoints Eric d'Esparbes as Chief Financial Officer
him to the team." d'Esparbes brings three decades of experience as a senior finance executive across the pharmaceutical, biotechnology, diagnostics, and energy industries. He has a proven track record building and leading finance organizations for companies with multi-billion-dollar
More news about: Antheia
Oct 21, 2025, 08:00 ET Boundless Futures Foundation grants $90,000 for Q3 to female company founders committed to both growth and good
sweeteners; a center providing creative programming for teens; and a company that is a pilot-scale biomanufacturing plant that helps food and agriculture biotechnology companies successfully scale precision fermentation. Since its inception in late 2023, Boundless Futures Foundation has awarded
More news about: Boundless Futures Foundation
Oct 21, 2025, 07:00 ET HanchorBio Secures US Patent for Innovative SIRPα/CD47 Fusion Protein HCB101
About HanchorBio Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (7827.TWO), a global biotechnology company specializing in immuno-oncology, is led by an experienced team of pharmaceutical industry veterans with a proven track record of success
More news about: HanchorBio Inc.
Oct 21, 2025, 06:59 ET Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata
WALTHAM, Mass., Oct. 21, 2025 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that
More news about: Q32 Bio
Oct 21, 2025, 06:00 ET Danaher Reports Third Quarter 2025 Results
Impairment charges related to technology and other intangible assets in the Biotechnology segment recorded in both the three and nine-month periods ended September 26, 2025 ($86 million pretax as reported in this line item, $58 million
More news about: Danaher Corporation
Oct 21, 2025, 05:00 ET Corra Group Advances Background Screening with AI to Improve Accuracy, Build Trust, and Elevate the Customer Experience
Futurist Amy Webb also describes the moment we're in as a "technology supercycle," where AI, biotechnology, and connected devices are reshaping how society and business operate. For
More news about: Corra Group
Oct 20, 2025, 19:39 ET BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES AND GRANT OF STOCK OPTIONS
receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about
More news about: BioVaxys Technology Corp.
Oct 20, 2025, 16:28 ET CaseBioscience® Launches CaseBio™ Culture and CaseBio™ Handling Media at ASRM 2025 After FDA 510(k) Clearance and Clinical Evaluation
PETERSBURG, Fla., Oct. 20, 2025 /PRNewswire/ -- CaseBioscience® is driving a new era of innovation in biotechnology by uniting Assisted Reproductive Technology (ART) with breakthroughs in stem cell science. Over the past three years, the company's research and
More news about: CaseBioscience Inc.
Oct 20, 2025, 14:31 ET Sōlaria Biō Announces New Bone Health Breakthrough with Bondia™
Sōlaria Biō, a biotechnology company pioneering natural solutions for healthy aging, today launched
More news about: Sōlaria Biō
Oct 20, 2025, 13:08 ET LabConnect Featured in Season Finale of Emmy-Nominated Series Tomorrow's World Today
About LabConnect LabConnect is redefining central laboratory services as a technology-driven partner for pharmaceutical and biotechnology companies. Our decentralized network model provides sponsors with access to the industry's most comprehensive global testing menu, supported by
More news about: LabConnect